Use of genetically engineered bone marrow-derived mesenchymal stem cells for glioma gene therapy

International Journal of Oncology

Volumn 35, Issue 6, 2009, Pages 1265-1270

  Amano, Shinji ^a   Li, Shaoyi ^a,b   Gu, Chunyu ^a   Gao, Yun ^a   Koizumi, Shinichiro ^a   Yamamoto, Seiji ^a   Terakawa, Susumu ^a   Namba, Hiroki ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Bystander effect; Glioma; Herpes simplex virus thymidine kinase; Mesenchymal stem cell; Suicide gene therapy

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE; ANTIVIRUS AGENT;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BYSTANDER EFFECT; CANCER GENE THERAPY; CANCER SURVIVAL; GENETIC ENGINEERING; GLIOMA; HERPES SIMPLEX VIRUS; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR VOLUME; ANIMAL; BRAIN TUMOR; GENE THERAPY; GENETICS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; METHODOLOGY; PHYSIOLOGY; SIMPLEXVIRUS; SPRAGUE DAWLEY RAT; SUICIDE TRANSGENE;

ANIMALS; ANTIVIRAL AGENTS; BONE MARROW CELLS; BRAIN NEOPLASMS; BYSTANDER EFFECT; GANCICLOVIR; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC ENGINEERING; GLIOMA; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; RATS; RATS, SPRAGUE-DAWLEY; SIMPLEXVIRUS; THYMIDINE KINASE;

EID: 73949139195     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000443     Document Type: Article

References (39)

1. De Angelis LM: Brain tumors. N Engl J Med 344: 114-123, 2001.
2. Lefranc F, Brotchi J and Kiss R: Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 23: 2411-2422, 2005.
3. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018, 2002.
4. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH and Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552, 1992.
5. Barzon L, Zanusso M, Colombo F and Palu G: Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas. Cancer Gene Ther 13: 539-554, 2006.
6. Aboody KS, Brown A, Rainov NG, et al: Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 97: 12846-12851, 2000.
7. Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL and Yu JS: The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 62: 5657-5663, 2002.
8. Wennersten A, Meier X, Holmin S, Wahlberg L and Mathiesen T: Proliferation, migration, and differentiation of human neural stem/progenitor cells after transplantation into a rat model of traumatic brain injury. J Neurosurg 100: 88-96, 2004.
9. Li S, Gao Y, Tokuyama T, et al: Genetically engineered neural stem cells migrate and suppress glioma cell growth at distant intracranial sites. Cancer Lett 251: 220-227, 2007.
10. Li S, Tokuyama T, Yamamoto J, Koide M, Yokota N and Namba H: Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells. Cancer Gene Ther 12: 600-607, 2005.
11. Lee J, Elkahloun AG, Messina SA, et al: Cellular and genetic characterization of human adult bone marrow-derived neural stem-like cells: a potential antiglioma cellular vector. Cancer Res 63: 8877-8889, 2003.
12. Nakamura K, Ito Y, Kawano Y, et al: Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 11: 1155-1164, 2004.
13. Nakamizo A, Marini F, Amano T, et al: Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65: 3307-3318, 2005.
14. Yuan X, Hu J, Belladonna ML, Black KL and Yu JS: Interleukin-23- expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. Cancer Res 66: 2630-2638, 2006.
15. Wu X, Hu J, Zhou L, et al: In vivo tracking of superparamagnetic iron oxide nanoparticle-labeled mesenchymal stem cell tropism to malignant gliomas using magnetic resonance imaging. Laboratory Investigation. J Neurosurg 108: 320-329, 2008.
16. Bexell D, Gunnarsson S, Tormin A, et al: Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther 17: 183-190, 2009.
17. Namba H, Iwadate Y, Tagawa M, et al: Evaluation of the bystander effect in experimental brain tumors bearing herpes simplex virus-thymidine kinase gene by serial magnetic resonance imaging. Hum Gene Ther 7: 1847-1852, 1996.
18. Namba H, Tagawa M, Iwadate Y, Kimura M, Sueyoshi K and Sakiyama S: Bystander effect-mediated therapy of experimental brain tumor by genetically engineered tumor cells. Hum Gene Ther 9: 5-11, 1998.
19. Li S, Tokuyama T, Yamamoto J, Koide M, Yokota N and Namba H: Potent bystander effect in suicide gene therapy using neural stem cells transduced with herpes simplex virus thymidine kinase gene. Oncology 69: 503-508, 2005.
20. Iwadate Y, Namba H, Tagawa M, Takenaga K, Sueyoshi K and Sakiyama S: In vivo bystander effect in the intracranial model with rat glioma cells reflects the clonal difference of HSV-TK positive cells. Int J Oncol 9: 521-525, 1996.
21. Miletic H, Fischer YH, Giroglou T, et al: Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma. Clin Cancer Res 13: 6761-6768, 2007.
22. Farrell E, Wielopolski P, Pavljasevic P, et al: Effects of iron oxide incorporation for long term cell tracking on MSC differentiation in vitro and in vivo. Biochem Biophys Res Commun 369: 1076-1081, 2008.
23. Roelants V, Labar D, De Meester C, et al: Comparison between adenoviral and retroviral vectors for the transduction of the thymidine kinase PET reporter gene in rat mesenchymal stem cells. J Nucl Med 49: 1836-1844, 2008.
24. Xiong Z, Cheng Z, Zhang X, et al: Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene. J Nucl Med 47: 130-139, 2006.
25. Yaghoubi SS, Barrio JR, Namavari M, et al: Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography. Cancer Gene Ther 12: 329-339, 2005.
26. Jacobs AH, Winkeler A, Hartung M, et al: Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes. Hum Gene Ther 14: 277-297, 2003.
27. Uchibori R, Okada T, Ito T, et al: Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J Gene Med 11: 373-381, 2009.
28. Kim SM, Lim JY, Park SI, et al: Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 68: 9614-9623, 2008.
29. Studeny M, Marini F, Champlin R, Zompetta C, Fidler I and Andreeff M: Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62: 3603-3608, 2002.
30. Kucerova L, Altanerova V, Matuskova M, Tyciakova S and Altaner C: Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 67: 6304-6313, 2007.
31. Ribot E, Bouzier-Sore AK, Bouchaud V, et al: Microglia used as vehicles for both inducible thymidine kinase gene therapy and MRI contrast agents for glioma therapy. Cancer Gene Ther 14: 724-737, 2007.
32. Miletic H, Fischer Y, Litwak S, et al: Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. Mol Ther 15: 1373-1381, 2007.
33. Birnbaum T, Roider J, Schankin CJ, et al: Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol 83: 241-247, 2007.
34. Robe PA, Nguyen-Khac MT, Lambert F, et al: Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. Int J Oncol 30: 283-290, 2007.
35. Jimenez T, Fox WP, Naus CC, Galipeau J and Belliveau DJ: Connexin over-expression differentially suppresses glioma growth and contributes to the bystander effect following HSV-thymidine kinase gene therapy. Cell Commun Adhes 13: 79-92, 2006.
36. Uhl M, Weiler M, Wick W, Jacobs AH, Weller M and Herrlinger U: Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas. Biochem Biophys Res Commun 328: 125-129, 2005.
37. Burrows FJ, Gore M, Smiley WR, et al: Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells. Cancer Gene Ther 9: 87-95, 2002.
38. Namba H, Iwadate Y, Kawamura K, Sakiyama S and Tagawa M: Efficacy of the bystander effect in the herpes simplex virus thymidine kinase-mediated gene therapy is influenced by the expression of connexin43 in the target cells. Cancer Gene Ther 8: 414-420, 2001.
39. Hayashi K, Lee JB, Maitani Y, Toyooka N, Nemoto H and Hayashi T: The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy. J Gene Med 8: 1056-1067, 2006.